Andor LLC completed its acquisition of Apogee Therapeutics, Inc. on 2026-09-03, according to the Form 8-K Apogee Therapeutics, Inc. filed with the SEC on 2026-09-03. The filing states a price of $12.5 million. Apogee Therapeutics, Inc. filed the report because the deal made it part of Andor LLC.
| Acquirer | Andor LLC |
|---|---|
| Acquired | Apogee Therapeutics, Inc. |
| Completed | 2026-09-03 |
| Price stated in the filing | $12.5 million |
| Reported by | Apogee Therapeutics, Inc. (APGE), the company acquired |
| Filing | Form 8-K, filed 2026-09-03 |
Want the whole picture on Andor LLC?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Andor LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Andor LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
Pursuant to the Merger Agreement, on September 3, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
The price, in the filing's words
The aggregate amount payable to all service providers of the Company who enter into such an agreement, including the named executive officers, is limited to $12,500,000.
More from the filing
As previously disclosed, on June 18, 2026, Apogee Therapeutics, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Andor LLC, a Delaware limited liability company and a wholly owned subsidiary of Guarantor ("Parent"), Andor Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and solely for the limited purposes set forth therein, AbbVie Inc., a Delaware corporation ("Guarantor" or "AbbVie").
Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.
Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"): (i) each share of voting common stock of the Company, par value $0.00001 per share, and each share of non-voting common stock of the Company, par value $0.00001 per share (each, a "Share"), outstanding immediately prior to the Effective Time, but excluding each Share (A) owned by the Company or any of its wholly owned subsidiaries, (B) held by Guarantor, Parent, Merger Sub or any other wholly owned subsidiary of Guarantor, and (C) held by a stockholder who had not voted in favor of the adoption of the
Quoted from Apogee Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Andor LLC reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Andor LLCLook up Andor LLC and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.